Xiamen Amoytop Biotech Co., Ltd. Class A 688278

ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been init

The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases.

Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of $25M USD from the exclusive license deal of pevifoscorvir sodium in Greater China with Xiamen Amoytop Biotech Co., Lt

Aligos remains eligible for up to $420m in milestones and tiered, high single-digit royalties on Amoytop’s net sales.

Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fund its development program in Greater ChinaAmoytop is a leading Chinese pharmaceutical company with commercially approved therapeutics, including PEGBING®, to treat chronic HBV infection SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmace

As global markets navigate a complex landscape marked by U.S. labor market weaknesses, geopolitical tensions, and fluctuating economic indicators, investors are keenly exploring opportunities in undervalued stocks. In this context, identifying stocks with strong fundamentals that may be trading below their intrinsic value could present promising value opportunities amidst the current market dynamics.

As global markets show signs of resilience, with major indices reaching new highs despite geopolitical tensions, investors are increasingly turning their attention to Asia for opportunities. In this environment, identifying stocks that are trading below their intrinsic value can be a strategic move, offering potential for growth as the region's economic landscape continues to evolve.

As global markets continue to navigate geopolitical tensions and economic shifts, Asian equities have shown resilience, with several indices experiencing notable gains. In this environment, identifying undervalued stocks becomes crucial for investors seeking opportunities amidst fluctuating market conditions.

As we enter 2026, Asian markets are navigating a complex landscape marked by mixed performances in major economies like China and Japan, with slight gains in manufacturing and technology sectors amid ongoing economic uncertainties. In this environment, identifying undervalued stocks requires a keen focus on intrinsic valuation estimates, as investors seek opportunities that offer potential value amidst fluctuating market conditions.

As global markets navigate a complex landscape of economic indicators and geopolitical tensions, investors are increasingly turning their attention to the Asian market for opportunities. In this environment, identifying undervalued stocks can be particularly rewarding, as these equities may offer significant potential relative to their intrinsic value.

As Asian markets navigate a landscape marked by mixed performances across major indices, investors are increasingly focused on identifying opportunities within the region. In this context, undervalued stocks present a compelling prospect for those seeking to capitalize on discrepancies between market prices and estimated intrinsic values, especially in light of recent economic indicators and policy developments.

As we approach the end of 2025, Asian markets have shown resilience with notable gains in key indices, despite global economic challenges and mixed signals from major economies. In this context, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors looking to capitalize on market inefficiencies.

As Asian markets continue to navigate a landscape of economic challenges and opportunities, investors are increasingly focused on identifying stocks that offer strong value propositions amid current conditions. In this context, selecting stocks priced below their estimated intrinsic value can be a strategic approach to capitalizing on potential market inefficiencies.

As global markets continue to navigate a complex landscape, Asian stocks have shown resilience, with indices like Japan's Nikkei 225 and China's CSI 300 posting gains amid optimism around artificial intelligence and economic growth prospects. In this environment, identifying potentially undervalued stocks can be crucial for investors seeking opportunities in Asia's diverse market landscape.

As global markets close out the year, Asian indices have shown resilience amid a mixed economic landscape, with China's stock markets experiencing gains despite broader concerns about growth and investment. In this environment, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

As 2025 draws to a close, the Asian markets are navigating a complex landscape marked by Japan's significant interest rate hike and mixed signals from China's economic indicators. In this environment, identifying stocks that may be undervalued compared to their intrinsic value can present opportunities for investors looking to capitalize on potential market inefficiencies. A good stock in such conditions is often characterized by strong fundamentals and resilience amid broader economic...

As Asian markets navigate a complex landscape marked by Japan's interest rate hike to its highest level in 30 years and China's mixed economic signals, investors are keenly observing opportunities that may arise from these developments. In such an environment, identifying stocks trading below their intrinsic value can provide potential entry points for those looking to capitalize on undervaluation amidst broader market fluctuations.

As global markets navigate a period marked by interest rate adjustments and fluctuating economic indicators, Asian stock markets continue to capture investor attention with their unique opportunities. In this environment, identifying stocks trading below their intrinsic value can be a strategic move for investors seeking potential growth, especially when these stocks are supported by strong fundamentals and favorable market conditions.

As global markets navigate the implications of interest rate adjustments and economic uncertainties, Asian markets are drawing attention with their unique challenges and opportunities. In this environment, discerning investors are on the lookout for stocks that may be trading below their intrinsic value, offering potential entry points in a market characterized by cautious optimism.